JIB-04, an H3K36me3 agonist, effectively suppressed KC activation induced by Men1 or Setd2 deletion by reactivating IL-10 expression and further alleviated CCL4-induced liver fibrosis symptoms. Here, SETD2 is linked to Hepatic fibrosis.